Virtual ISPOR Europe 2020, “Improving Health: Establishing Incentives and Sharing Value,” will now be held as a completely virtual conference. Content for Virtual ISPOR Europe 2020 will be delivered both synchronously and asynchronously, through live and on-demand sessions released leading up to the […]
Latest Stories
ISPOR’s CSO Dr. Lucinda Orsini shares views on use of RWE by regulators and HTAs
In this interview with Lucinda Orsini, D.P.M., M.P.H., the Associate Chief Science Officer for the Professional Society for Health Economics and Outcomes Research (ISPOR), she shares her views on navigating the opportunities and challenges of working with RWE. Dr. Orsini sees substantial […]
Aetion analyzes RWE impact in 4 recent FDA decisions in infectious disease
Senior Directors from Aetion (Purpura and Harvey) analyzed four approvals for products intended to treat or prevent infectious diseases from 2019 that included RWE studies to highlight how foreign postmarketing data improves understanding of a product’s risk-benefit profile. The products examined […]
A Digital Bridge To Real-Time COVID-19 Data
Several years ago, the Digital Bridge collaborative was formed, consisting of representatives from three key stakeholder communities: public health, the health care delivery system, and electronic health record (EHR) vendors. They concluded that the ubiquitous footprint of electronic health records […]
AMCP Introduces AMCP Collaborate online community to engage in discussions of managed care
AMCP, the organization for managed care pharmacists, today introduced AMCP Collaborate, an online community designed to give members a new platform to engage with each other in discussions impacting managed care pharmacy. AMCP Collaborate will have private communities for the following groups: […]
5 Questions for the New Chair of NICE Sharmila Nebhrajani
S. Nebharajani assumed the role of chair of NICE in May 2020, most recently serving as CEO of Wilton Park, leading the Global Health program looking at issues of AI and data for health systems in Africa, Asia, among other responsibilities. Medscape UK sat down for an interview, exploring […]
Former FDA Commish Califf: Weighing the Benefits & Risks of the Growing Number of Observational Treatment Assessments
In a recently published JAMA Viewpoint, former FDA Commissioner Robert Califf and colleagues mused about a growing concern about inferring causation about benefits and risks of potential therapeutics for COVID-19 derived from nonrandomized studies. The authors mused, " whether these reports just […]
New Report: Provider Perceptions of Value-Based Care
Provider Perceptions of Value-Based Care aimed to understand provider views on value-based care and their partnership with private and public payers to implement these models. Highlights from the 21-page report, released April 2020 from Xtelligent Healthcare Media, include Provider […]
Trump v. Pharma: a “Kinda Sorta” War
Politico summarizes Trump's "kinda sorta" war with pharma, kicked off last week with presidential tweets about "nasty" drug ads that "lied" about the impact of his pricing executive orders on senior's drug premiums and the price of prescription drugs. It's unclear exactly which drug ads he was […]
Unsupported Price Hikes: Drug manufacturers will be penalized in NASHP’s new model bill
The National Academy for State Health Policy’s (NASHP) newly introduced model law, an Act to Protect Consumers from Unsupported Price Increases on Prescription Drugs, charges substantial fines on pharmaceutical manufacturers that impose unjustified price increases and then uses the fines’ revenues […]
